Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Recruiting phase 2 trial of adaptive de-intensified radiotherapy guided by circulating tumor DNA in HPV-associated oropharyngeal cancer (planned n=45).

Ohio State University Comprehensive Cancer Center